LENSAR, Inc. - Common Stock (LNSR)

LENSAR (NASDAQ:LNSR) reported second-quarter 2026 revenue growth of 18% as the company continued to rebuild commercial momentum following the termination of its proposed merger with Alcon near the end of the first quarter. Chief Executive Officer Nick Curtis said the company returned to operating i

Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's pre-market session. The company's market cap stands at $7.2 million. LENSAR (NASDAQ:LNSR) shares increased by

Lensar (LNSR) Q1 2026 Earnings Transcript

LENSAR, Inc., a commercial-stage medical device company.

Lensar (LNSR) Q4 2025 Earnings Transcript

LENSAR (NASDAQ:LNSR) executives told investors on Thursday that the company is moving past a “transaction-related holding pattern” after the termination of its planned merger, and is now refocusing on rebuilding commercial momentum around its ALLY femtosecond laser cataract platform. Management said

Lensar said that its deal with Alcon is unlikely to receive necessary regulatory approvals in the U.S. by April 23 or even by July 23.

FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.

Alcon is set to acquire LENSAR Inc. in a $356 million deal. This acquisition includes LENSAR's advanced cataract laser technologies, boosting Alcon's offerings in femtosecond laser-assisted cataract surgery.

LNSR stock results show that LENSAR missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Buying stocks under $10 might be one of the best ways to breach that million mark. Take a look at these three potential candidates.

LNSR stock results show that LENSAR beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its fourth quarter.

Gainers AgileThought, Inc. (NASDAQ: AGIL) rose 96.5% to $0.3046 in pre-market trading after falling 17% on Tuesday.